Tenaya Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Tenaya Therapeutics Stock-Based Compensation Growth & History (TNYA)
Tenaya Therapeutics's stock-based compensation was $13.0M for fiscal 2025.
View full Tenaya Therapeutics company overviewTenaya Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.0M | −$3.5M | −20.94% |
| 2024 | 2024-12-31 | $16.5M | $1.2M | +7.79% |
| 2023 | 2023-12-31 | $15.3M | $3.8M | +33.50% |
| 2022 | 2022-12-31 | $11.5M | $8.5M | +288.71% |
| 2021 | 2021-12-31 | $3.0M | $2.2M | +298.11% |
| 2020 | 2020-12-31 | $741,000 | — | — |
Tenaya Therapeutics quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.7M | −$1.9M | −53.22% |
| Q1 2026 | 2026-03-31 | $2.2M | −$1.5M | −41.14% |
| Q4 2025 | 2025-12-31 | $2.7M | −$1.0M | −26.98% |
| Q3 2025 | 2025-09-30 | $2.9M | −$973,000 | −24.90% |
| Q2 2025 | 2025-06-30 | $3.6M | −$975,000 | −21.15% |
| Q1 2025 | 2025-03-31 | $3.7M | −$493,000 | −11.67% |
| Q4 2024 | 2024-12-31 | $3.8M | −$190,000 | −4.81% |
| Q3 2024 | 2024-09-30 | $3.9M | −$108,000 | −2.69% |
| Q2 2024 | 2024-06-30 | $4.6M | $780,000 | +20.36% |
| Q1 2024 | 2024-03-31 | $4.2M | $710,000 | +20.20% |
| Q4 2023 | 2023-12-31 | $3.9M | $762,000 | +23.91% |
| Q3 2023 | 2023-09-30 | $4.0M | $841,000 | +26.50% |
| Q2 2023 | 2023-06-30 | $3.8M | $819,000 | +27.19% |
| Q1 2023 | 2023-03-31 | $3.5M | $1.4M | +67.81% |
| Q4 2022 | 2022-12-31 | $3.2M | $2.1M | +204.10% |
| Q3 2022 | 2022-09-30 | $3.2M | $2.2M | +227.89% |
| Q2 2022 | 2022-06-30 | $3.0M | $2.5M | +500.00% |
| Q1 2022 | 2022-03-31 | $2.1M | $1.7M | +384.72% |
| Q4 2021 | 2021-12-31 | $1.0M | — | — |
| Q3 2021 | 2021-09-30 | $968,000 | $770,000 | +388.89% |
| Q2 2021 | 2021-06-30 | $502,000 | $317,000 | +171.35% |
| Q1 2021 | 2021-03-31 | $432,000 | — | — |
| Q3 2020 | 2020-09-30 | $198,000 | — | — |
| Q2 2020 | 2020-06-30 | $185,000 | — | — |
Tenaya Therapeutics stock-based compensation trends
Over the last five fiscal years, Tenaya Therapeutics's stock-based compensation increased from $741,000 to $13.0M, a change of $12.3M. The latest reported quarter, Q2 2026, shows $1.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tenaya Therapeutics source filings ↗